What We Learned about the Feasibility of Gene Electrotransfer for Vaccination on a Model of COVID-19 Vaccine

DNA vaccination is one of the emerging approaches for a wide range of applications, including prophylactic vaccination against infectious diseases and therapeutic vaccination against cancer. The aim of this study was to evaluate the feasibility of our previously optimized protocols for gene electrotransfer (GET)-mediated delivery of plasmid DNA into skin and muscle tissues on a model of COVID-19 vaccine. Plasmids encoding the SARS-CoV-2 proteins spike (S) and nucleocapsid (N) were used as the antigen source, and a plasmid encoding interleukin 12 (IL-12) was used as an adjuvant. Vaccination was performed in the skin or muscle tissue of C57BL/6J mice on days 0 and 14 (boost). Two weeks after the boost, blood, spleen, and transfected tissues were collected to determine the expression of S, N, IL-12, serum interferon-γ, the induction of antigen-specific IgG antibodies, and cytotoxic T-cells. In accordance with prior in vitro experiments that indicated problems with proper expression of the S protein, vaccination with S did not induce S-specific antibodies, whereas significant induction of N-specific antibodies was detected after vaccination with N. Intramuscular vaccination outperformed skin vaccination and resulted in significant induction of humoral and cell-mediated immunity. Moreover, both boost and adjuvant were found to be redundant for the induction of an immune response. Overall, the study confirmed the feasibility of the GET for DNA vaccination and provided valuable insights into this approach.

[1]  G. Serša,et al.  Tumor cell-based vaccine contributes to local tumor irradiation by eliciting a tumor model-dependent systemic immune response , 2022, Frontiers in Immunology.

[2]  P. Strojan,et al.  Treatment of Skin Tumors with Intratumoral Interleukin 12 Gene Electrotransfer in the Head and Neck Region: A First-in-human Clinical Trial Protocol , 2022, Radiology and oncology.

[3]  G. Vandermeulen,et al.  Combination of DNA Vaccine and Immune Checkpoint Blockades Improves the Immune Response in an Orthotopic Unresectable Glioblastoma Model , 2022, Pharmaceutics.

[4]  Haocai Chang,et al.  Vaccines for COVID-19: A Systematic Review of Immunogenicity, Current Development, and Future Prospects , 2022, Frontiers in Immunology.

[5]  P. Moss.  The T cell immune response against SARS-CoV-2 , 2022, Nature Immunology.

[6]  Y. Sung,et al.  Safety and immunogenicity of two recombinant DNA COVID-19 vaccines containing the coding regions of the spike or spike and nucleocapsid proteins: an interim analysis of two open-label, non-randomised, phase 1 trials in healthy adults , 2022, The Lancet Microbe.

[7]  J. Lammertyn,et al.  Potent neutralizing anti-SARS-CoV-2 human antibodies cure infection with SARS-CoV-2 variants in hamster model , 2021, bioRxiv.

[8]  F. Rahbarizadeh,et al.  A brief review on DNA vaccines in the era of COVID-19 , 2021, Future virology.

[9]  J. Kim,et al.  SARS-CoV-2 DNA Vaccine INO-4800 Induces Durable Immune Responses Capable of Being Boosted in a Phase 1 Open-Label Trial , 2021, medRxiv.

[10]  Ilya J. Finkelstein,et al.  Expression and characterization of SARS-CoV-2 spike proteins , 2021, Nature Protocols.

[11]  Y. Ramot,et al.  Toxicity and Local Tolerance of COVID- eVax, a Plasmid DNA Vaccine for SARS-CoV-2, Delivered by Electroporation , 2021, Toxicologic pathology.

[12]  G. Ciliberto,et al.  COVID-eVax, an electroporated DNA vaccine candidate encoding the SARS-CoV-2 RBD, elicits protective responses in animal models , 2021, Molecular Therapy.

[13]  K. Stiasny,et al.  Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action , 2021, NPJ vaccines.

[14]  Enrico Maestri.  The 3Rs Principle in Animal Experimentation: A Legal Review of the State of the Art in Europe and the Case in Italy , 2021, Biotech (Basel (Switzerland)).

[15]  M. Čemažar,et al.  Mutational burden, MHC-I expression and immune infiltration as limiting factors for in situ vaccination by TNFα and IL-12 gene electrotransfer. , 2021, Bioelectrochemistry.

[16]  B. Pulendran,et al.  Emerging concepts in the science of vaccine adjuvants , 2021, Nature reviews. Drug discovery.

[17]  D. Prazeres,et al.  mRNA vaccines manufacturing: Challenges and bottlenecks , 2021, Vaccine.

[18]  M. Čemažar,et al.  Potentiation of electrochemotherapy effectiveness by immunostimulation with IL-12 gene electrotransfer in mice is dependent on tumor immune status. , 2021, Journal of controlled release : official journal of the Controlled Release Society.

[19]  D. Weiner,et al.  Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial , 2020, EClinicalMedicine.

[20]  Daniel W. Kulp,et al.  Harnessing Recent Advances in Synthetic DNA and Electroporation Technologies for Rapid Vaccine Development Against COVID-19 and Other Emerging Infectious Diseases , 2020, Frontiers in Medical Technology.

[21]  E. Karita,et al.  Acceptability and tolerability of repeated intramuscular electroporation of Multi-antigenic HIV (HIVMAG) DNA vaccine among healthy African participants in a phase 1 randomized controlled trial , 2020, PloS one.

[22]  M. Lenardo,et al.  A guide to cancer immunotherapy: from T cell basic science to clinical practice , 2020, Nature Reviews Immunology.

[23]  D. Weiner,et al.  DNA vaccines: prime time is now , 2020, Current Opinion in Immunology.

[24]  M. Čemažar,et al.  Development of Tumor Cell-Based Vaccine with IL-12 Gene Electrotransfer as Adjuvant , 2020, Vaccines.

[25]  Margaret A. Liu.  A Comparison of Plasmid DNA and mRNA as Vaccine Technologies , 2019, Vaccines.

[26]  Bin Li,et al.  Nanoscale platforms for messenger RNA delivery. , 2019, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.

[27]  M. Rols,et al.  Safe and efficient novel approach for non-invasive gene electrotransfer to skin , 2018, Scientific Reports.

[28]  Dominika Hobernik,et al.  DNA Vaccines—How Far From Clinical Use? , 2018, International journal of molecular sciences.

[29]  M. Rols,et al.  Safe and efficient novel approach for non-invasive gene electrotransfer to skin , 2018, Scientific Reports.

[30]  L. Thoring,et al.  High-yield production of “difficult-to-express” proteins in a continuous exchange cell-free system based on CHO cell lysates , 2017, Scientific Reports.

[31]  I. Frazer,et al.  Interferon-γ derived from cytotoxic lymphocytes directly enhances their motility and cytotoxicity , 2017, Cell Death & Disease.

[32]  M. Haniffa,et al.  Antigen-Presenting Cells in the Skin. , 2017, Annual review of immunology.

[33]  E. Gowans,et al.  Delivery methods to increase cellular uptake and immunogenicity of DNA vaccines. , 2016, Vaccine.

[34]  G. Vandermeulen,et al.  Electrotransfer parameters as a tool for controlled and targeted gene expression in skin , 2016, Molecular therapy. Nucleic acids.

[35]  Damijan Miklavcic,et al.  Gene Electrotransfer: A Mechanistic Perspective , 2016, Current gene therapy.

[36]  N. Petrovsky.  Comparative Safety of Vaccine Adjuvants: A Summary of Current Evidence and Future Needs , 2015, Drug Safety.

[37]  J. Završnik,et al.  Gene electrotransfer of plasmid AMEP, an integrin-targeted therapy, has antitumor and antiangiogenic action in murine B16 melanoma , 2015, Gene Therapy.

[38]  P. McKay,et al.  Enhanced Immunogenicity of an HIV-1 DNA Vaccine Delivered with Electroporation via Combined Intramuscular and Intradermal Routes , 2014, Journal of Virology.

[39]  Donald K Carter,et al.  Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and impact of intramuscular electroporation for delivery. , 2013, The Journal of infectious diseases.

[40]  D. Weiner,et al.  Synthetic DNA vaccine strategies against persistent viral infections , 2013, Expert review of vaccines.

[41]  N. Sardesai,et al.  IL-12 DNA as molecular vaccine adjuvant increases the cytotoxic T cell responses and breadth of humoral immune responses in SIV DNA vaccinated macaques , 2012, Human vaccines & immunotherapeutics.

[42]  A. Bowie,et al.  Cytosolic DNA sensors regulating type I interferon induction. , 2011, Trends in immunology.

[43]  D. Scherman,et al.  Genetic immunization with plasmid DNA mediated by electrotransfer. , 2011, Human gene therapy.

[44]  D. Coppola,et al.  Evaluation of a Novel Non-Penetrating Electrode for Use in DNA Vaccination , 2011, PloS one.

[45]  M. Marino,et al.  Skeletal muscle cells: from local inflammatory response to active immunity , 2011, Gene Therapy.

[46]  J. Barnett,et al.  Interleukin 12 a Key Immunoregulatory Cytokine in Infection Applications , 2010, International journal of molecular sciences.

[47]  Michele A. Kutzler,et al.  DNA vaccines: ready for prime time? , 2008, Nature Reviews Genetics.

[48]  Simona Kranjc,et al.  Gene Electrotransfer into Murine Skeletal Muscle: A Systematic Analysis of Parameters for Long-term Gene Expression , 2008, Technology in cancer research & treatment.

[49]  P. Pisa,et al.  Enhancement of cellular immune response to a prostate cancer DNA vaccine by intradermal electroporation. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[50]  N. Pavselj,et al.  DNA electrotransfer into the skin using a combination of one high- and one low-voltage pulse. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[51]  C. Alving,et al.  Immunization with DNA through the skin. , 2003, Methods.

[52]  J. Ulmer,et al.  Increased DNA Vaccine Delivery and Immunogenicity by Electroporation In Vivo , 2000, The Journal of Immunology.

[53]  J. Kim,et al.  IL-12 gene as a DNA vaccine adjuvant in a herpes mouse model: IL-12 enhances Th1-type CD4+ T cell-mediated protective immunity against herpes simplex virus-2 challenge. , 1999, Journal of immunology.

[54]  J. Zhang,et al.  DNA immunization: ubiquitination of a viral protein enhances cytotoxic T-lymphocyte induction and antiviral protection but abrogates antibody induction , 1997, Journal of virology.

[55]  R. Siliciano,et al.  Targeting of HIV-1 Antigens for Rapid Intracellular Degradation Enhances Cytotoxic T Lymphocyte (CTL) Recognition and the Induction of De Novo CTL Responses In Vivo After Immunization , 1997, The Journal of experimental medicine.

[56]  O. Iordache,et al.  Technologies , 2018, Studies in Systems, Decision and Control.

[57]  Christopher B Wilson,et al.  Regulation of interferon-gamma during innate and adaptive immune responses. , 2007, Advances in immunology.

[58]  A. Folgori,et al.  Genetic vaccination by gene electro-transfer in non-human primates , 2006 .

[59]  M. King,et al.  Search For: , 2006 .

[60]  C. Bona,et al.  Genetic Immunization , 2000, Springer US.

[61]  G. Trinchieri.  Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. , 1995, Annual review of immunology.